![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Christina Shaw & William Gibson. (2023) Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder. Therapeutics and Clinical Risk Management 19, pages 27-33.
Read now
Read now
Dudley Robinson, Miriam O’Kane & Linda Cardozo. (2023) Adherence to Overactive Bladder Syndrome Treatments Recent Developments and Future Perspectives. International Journal of Women's Health 15, pages 799-811.
Read now
Read now
Miriam O’Kane, Dudley Robinson, Linda Cardozo, Adrian Wagg & Paul Abrams. (2022) Mirabegron in the Management of Overactive Bladder Syndrome. International Journal of Women's Health 14, pages 1337-1350.
Read now
Read now
Carlo Gandi & Emilio Sacco. (2021) Pharmacological Management of Urinary Incontinence: Current and Emerging Treatment. Clinical Pharmacology: Advances and Applications 13, pages 209-223.
Read now
Read now
Eladio Fernández-Liz, Pere Vivó-Tristante, Antonio Aranzana-Martínez, Maria Estrella Barceló-Colomer, Maria Larrosa-Garcia, José Luís del Val García & Elisabeth Martín-Gracia. (2021) Long-term effectiveness of an intervention to enhance mirabegron use revision and its deprescribing: 36-month follow-up of a quasi-experimental trial in primary care. Current Medical Research and Opinion 37:4, pages 703-710.
Read now
Read now
Tomasz Rechberger & Andrzej Wróbel. (2021) Evaluating vibegron for the treatment of overactive bladder. Expert Opinion on Pharmacotherapy 22:1, pages 9-17.
Read now
Read now
Asad Makhani, Miriam Thake & William Gibson. (2020) Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient. Clinical Interventions in Aging 15, pages 575-581.
Read now
Read now
D. Robinson & L. Cardozo. (2019) Managing overactive bladder. Climacteric 22:3, pages 250-256.
Read now
Read now
Riccardo Bientinesi & Emilio Sacco. (2018) Managing urinary incontinence in women - a review of new and emerging pharmacotherapy. Expert Opinion on Pharmacotherapy 19:18, pages 1989-1997.
Read now
Read now
Christopher R Chapple & Emad Siddiqui. (2017) Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. Expert Review of Clinical Pharmacology 10:2, pages 131-151.
Read now
Read now
Dudley Robinson, Ganesh Thiagamoorthy & Linda Cardozo. (2016) A drug safety evaluation of mirabegron in the management of overactive bladder. Expert Opinion on Drug Safety 15:5, pages 689-696.
Read now
Read now
Roopali Karmarkar & Vik Khullar. (2015) Emerging drugs for overactive bladder. Expert Opinion on Emerging Drugs 20:4, pages 613-624.
Read now
Read now
Articles from other publishers (31)
Jieye Lin, Johan Unge & Tamir Gonen. (2023) Distinct Conformations of Mirabegron Determined by MicroED. Advanced Science 10:34.
Crossref
Crossref
Mohammad Abrar Alam. 2023. Privileged Scaffolds in Drug Discovery. Privileged Scaffolds in Drug Discovery
1
19
.
Elisa Doukbi, Astrid Soghomonian, Coralie Sengenès, Shaista Ahmed, Patricia Ancel, Anne Dutour & Bénédicte Gaborit. (2022) Browning Epicardial Adipose Tissue: Friend or Foe?. Cells 11:6, pages 991.
Crossref
Crossref
Peter Aldiss, Jo E. Lewis, Irene Lupini, Ian Bloor, Ramyar Chavoshinejad, David J. Boocock, Amanda K. Miles, Francis J. P. Ebling, Helen Budge & Michael E. Symonds. (2022) Cold Exposure Drives Weight Gain and Adiposity following Chronic Suppression of Brown Adipose Tissue. International Journal of Molecular Sciences 23:3, pages 1869.
Crossref
Crossref
Dudley Robinson & Linda Cardozo. 2021. Pelvic Floor Disorders. Pelvic Floor Disorders
351
363
.
Žiga Jakopin. (2020) 2-aminothiazoles in drug discovery: Privileged structures or toxicophores?. Chemico-Biological Interactions 330, pages 109244.
Crossref
Crossref
Tracey Seipel & Alexander G. Schauss. 2020. Textbook of Natural Medicine. Textbook of Natural Medicine
1533
1544.e3
.
Sophia Delpe Goodridge & Roger Dmochowski. 2020. Urologic Principles and Practice. Urologic Principles and Practice
457
473
.
Dudley Robinson & Linda Cardozo. (2019) The Role of Local Hormone Replacement in Overactive Bladder. Current Bladder Dysfunction Reports 14:4, pages 342-349.
Crossref
Crossref
Lei Hao, Sheyenne Scott, Mehrnaz Abbasi, Yujiao Zu, Md Shahjalal Hossain Khan, Yang Yang, Dayong Wu, Ling Zhao & Shu Wang. (2019) Beneficial Metabolic Effects of Mirabegron In Vitro and in High-Fat Diet-Induced Obese Mice. Journal of Pharmacology and Experimental Therapeutics 369:3, pages 419-427.
Crossref
Crossref
Sophia Delpe Goodridge & Roger R. Dmochowski. 2019. Contemporary Pharmacotherapy of Overactive Bladder. Contemporary Pharmacotherapy of Overactive Bladder
115
131
.
Sara J. Allison & William Gibson. (2018) Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. Therapeutic Advances in Urology 10:12, pages 411-419.
Crossref
Crossref
Feng Xu, Birgit Kosjek, Fabien L. Cabirol, Haibin Chen, Richard Desmond, Jeonghan Park, Anupam P. Gohel, Steven J. Collier, Derek J. Smith, Zhuqing Liu, Jacob M. Janey, John Y. L. Chung & Oscar Alvizo. (2018) Synthesis of Vibegron Enabled by a Ketoreductase Rationally Designed for High pH Dynamic Kinetic Reduction. Angewandte Chemie International Edition 57:23, pages 6863-6867.
Crossref
Crossref
Feng Xu, Birgit Kosjek, Fabien L. Cabirol, Haibin Chen, Richard Desmond, Jeonghan Park, Anupam P. Gohel, Steven J. Collier, Derek J. Smith, Zhuqing Liu, Jacob M. Janey, John Y. L. Chung & Oscar Alvizo. (2018) Synthesis of Vibegron Enabled by a Ketoreductase Rationally Designed for High pH Dynamic Kinetic Reduction. Angewandte Chemie 130:23, pages 6979-6983.
Crossref
Crossref
Emma D. Deeks. (2018) Mirabegron: A Review in Overactive Bladder Syndrome. Drugs 78:8, pages 833-844.
Crossref
Crossref
Renee D. Schmid & Lynn R. Hovda. (2017) Mirabegron Toxicosis in Dogs: a Retrospective Study. Journal of Medical Toxicology 14:2, pages 160-167.
Crossref
Crossref
Sanjay Sinha. (2019) Overactive Bladder: Changing Paradigms in Current Guidelines and Pharmacotherapy. Annals of SBV 6:2, pages 15-20.
Crossref
Crossref
Jan Otevrel & Pavel Bobal. (2017) Diamine-Tethered Bis(thiourea) Organocatalyst for Asymmetric Henry Reaction. The Journal of Organic Chemistry 82:16, pages 8342-8358.
Crossref
Crossref
Yasuhiro Wada, Seiji Nakano, Akifumi Morimoto, Ken-ichi Kasahara, Takahiko Hayashi, Yoshio Takada, Hiroko Suzuki, Michiko Niwa-Sakai, Shigeki Ohashi, Mutsuhiro Mori, Takatsugu Hirokawa & Satoshi Shuto. (2017)
Discovery of Novel Indazole Derivatives as Orally Available β
3
-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects
. Journal of Medicinal Chemistry 60:8, pages 3252-3265.
Crossref
Crossref
Peter Aldiss, Graeme Davies, Rachel Woods, Helen Budge, Harold S. Sacks & Michael E. Symonds. (2017) ‘Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. International Journal of Cardiology 228, pages 265-274.
Crossref
Crossref
Bart H. Harper, Liping Wang, Cheng Zhu, Nam F. Kar, Bing Li, Christopher R. Moyes, Stephen D. Goble, Melissa Costa, Karen Dingley, Jerry Di Salvo, Sookhee N. Ha, Amanda Hurley, Xiaofang Li, Randy R. Miller, Hiroshi Nagabukuro, Gino M. Salituro, Sean Smith, Mary Struthers, Jeffrey J. Hale, Scott D. Edmondson & Richard Berger. (2017) Investigation of piperazine benzamides as human β 3 adrenergic receptor agonists for the treatment of overactive bladder. Bioorganic & Medicinal Chemistry Letters 27:4, pages 1094-1098.
Crossref
Crossref
Bronagh McDonnell & Lori Ann Birder. (2017) Recent advances in pharmacological management of urinary incontinence. F1000Research 6, pages 2148.
Crossref
Crossref
S.D. Edmondson. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
714
737
.
Emilio Sacco, Riccardo Bientinesi, Pierfrancesco Bassi & Diego Currò. (2016) Pharmacological methods for the preclinical assessment of therapeutics for OAB: an up-to-date review. International Urogynecology Journal 27:11, pages 1633-1644.
Crossref
Crossref
Michael S. Saporito, Eva Zuvich & Amy DiCamillo. (2016) A Mouse Model of Furosemide‐Induced Overactive Bladder. Current Protocols in Pharmacology 74:1.
Crossref
Crossref
Sara Persyn, Stefan De Wachter, Jean-Jacques Wyndaele, Jane Eastham & James Gillespie. (2016) The actions of isoprenaline and mirabegron in the isolated whole rat and guinea pig bladder. Autonomic Neuroscience 198, pages 19-27.
Crossref
Crossref
Scott D. Edmondson, Cheng Zhu, Nam Fung Kar, Jerry Di Salvo, Hiroshi Nagabukuro, Beatrice Sacre-Salem, Karen Dingley, Richard Berger, Stephen D. Goble, Gregori Morriello, Bart Harper, Christopher R. Moyes, Dong-Ming Shen, Liping Wang, Richard Ball, Aileen Fitzmaurice, Tara Frenkl, Loise N. Gichuru, Sookhee Ha, Amanda L. Hurley, Nina Jochnowitz, Dorothy Levorse, Shruty Mistry, Randy R. Miller, James Ormes, Gino M. Salituro, Anthony Sanfiz, Andra S. Stevenson, Katherine Villa, Beata Zamlynny, Stuart Green, Mary Struthers & Ann E. Weber. (2016)
Discovery of Vibegron: A Potent and Selective β
3
Adrenergic Receptor Agonist for the Treatment of Overactive Bladder
. Journal of Medicinal Chemistry 59:2, pages 609-623.
Crossref
Crossref
Cheng Zhu, Nam F. Kar, Bing Li, Melissa Costa, Karen H. Dingley, Jerry Di Salvo, Sookhee N. Ha, Amanda L. Hurley, Xiaofang Li, Randy R. Miller, Gino M. Salituro, Mary Struthers, Ann E. Weber, Jeffrey J. Hale & Scott D. Edmondson. (2016) Discovery of benzamides as potent human β3 adrenergic receptor agonists. Bioorganic & Medicinal Chemistry Letters 26:1, pages 55-59.
Crossref
Crossref
Ilias Giarenis, Dudley Robinson & Linda Cardozo. (2015) Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects. Drugs 75:15, pages 1707-1713.
Crossref
Crossref
J. Eastham, C. Stephenson, K. Korstanje & J. I. Gillespie. (2015) The expression of β3-adrenoceptor and muscarinic type 3 receptor immuno-reactivity in the major pelvic ganglion of the rat. Naunyn-Schmiedeberg's Archives of Pharmacology 388:7, pages 695-708.
Crossref
Crossref
Emilio Sacco & Riccardo Bientinesi. (2014) Innovative pharmacotherapies for women with overactive bladder: where are we now and what is in the pipeline?. International Urogynecology Journal 26:5, pages 629-640.
Crossref
Crossref